Treatment of Staphylococcus aureus infections utilizing antibodies that bind to fibronectin binding proteins
US8211432B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 31, 2006 |
| Grant date | Jul 3, 2012 |
| Priority date | — |
| Expiry date | Jun 7, 2029 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/78
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.